Shionogi & Co., Ltd., a leading company of anti-infective drugs, announced last week that it had received approval in Japan for the additional dosage and administration of “Finibax® 0.25g IV Solution” and "Finibax® 0.25g IV Solution Kit” (generic name: doripenem hydrate), carbapenem antibiotic products, which allows the products to be administered 3g as a maximum daily dose. 

"Finibax® 0.25g IV Solution”, launched in September, 2005 in Japan, is a parenteral injection of carbapenem antibiotic discovered and developed by Shionogi and exhibits a strong and broad antibacterial spectrum, covering gram-positive to gram-negative bacteria as well as aerobic to anaerobic bacteria. Since this antibiotic has a strong antibacterial activity against Pseudomonas aeruginosa, which causes a remedial problem as one of offending bacteria of serious and intractable infections, it has been prescribed with high usability in treating various types of moderate to serious infections. 

Finibax®/Doribax® have already been approved in 78 countries of the world and the approval of the maximum daily dose of 3g in Japan is the first achievement in the world.